Abstract
To date, the pharmacological activity and clinical benefits of omalizumab have been well described, however several questions still remain unanswered, such as the moment to withdraw the drug as well as the possible biological markers that may be useful to do so. In the present case report, we describe our experience with our dose-reduction protocol in a middle-aged patient and elucidate the usefulness of free IgE levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
